BSV to invest Rs 200cr on bio-pharma mfg plant in Genome Valley

Bharat Serums and Vaccines Limited (BSV) hosted the groundbreaking ceremony of its new manufacturing plant at Genome Valley in Hyderabad on Thursday. The new facility will cover an area of 10 acres and involve an investment of Rs 200 crore. It aims to provide long-term employment opportunities to the people of the Telangana State as well as upskilling of capabilities.

With this manufacturing facility, BSV aims to significantly increase its capacity in producing injectables with the commissioning of the fill-finish formulation line in phase 1 and an additional multi-product line in phase 2 of the project. As the chief guest on the occasion, Telangana IT & Industries Minister KT Rama Rao welcomed BSV to Hyderabad, the ‘Vaccine Capital of the World’.

He said, “More than 900 crore doses of vaccines are being manufactured and exported from Genome Valley to India and rest of the world. From next year, the capacity will increase to 1,400 crore doses. Hyderabad has the largest number of USFDA-approved sites with 214 manufacturing units, while New Jersey in the US stands second largest in the world having 189 USFDA-approved facilities.”